esperion therapeutics, inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, ldl-c lowering therapies for the treatment of patients with hypercholesterolemia. etc-1002, the company's lead product candidate, is an inhibitor of atp citrate lyase, a well-characterized enzyme on the cholesterol biosynthesis pathway; the same pathway that includes hmg-coa reductase, the enzyme target of statins. the company has successfully completed its phase 1 and phase 2 development programs for etc-1002, and plans to initiate its etc-1002 phase 3 development program by the end of 2015. for more information, please visit www.esperion.com.
Company profile
Ticker
ESPR
Exchange
Website
CEO
Timothy Mayleben
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
HDL THERAPEUTICS INC
SEC CIK
ESPR stock data
Latest filings (excl ownership)
DEF 14A
Definitive proxy
11 Apr 24
ARS
2023 FY
Annual report to shareholders
11 Apr 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Esperion Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 24
8-K
Esperion Announces Proposed Public Offering of Common Stock
22 Jan 24
424B5
Prospectus supplement for primary offering
22 Jan 24
8-K
Regulation FD Disclosure
18 Jan 24
424B5
Prospectus supplement for primary offering
18 Jan 24
8-K
Results of Operations and Financial Condition
11 Jan 24
8-K
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation
3 Jan 24
Transcripts
ESPR
Earnings call transcript
2023 Q4
27 Feb 24
ESPR
Earnings call transcript
2023 Q3
7 Nov 23
ESPR
Earnings call transcript
2023 Q2
1 Aug 23
ESPR
Earnings call transcript
2023 Q1
9 May 23
ESPR
Earnings call transcript
2022 Q4
21 Feb 23
ESPR
Earnings call transcript
2022 Q3
1 Nov 22
ESPR
Earnings call transcript
2022 Q2
2 Aug 22
ESPR
Earnings call transcript
2022 Q1
3 May 22
ESPR
Earnings call transcript
2021 Q4
22 Feb 22
ESPR
Earnings call transcript
2021 Q3
2 Nov 21
Latest ownership filings
4
Eric Warren
15 Mar 24
4
Joanne M. Foody
15 Mar 24
4
Benjamin Looker
15 Mar 24
4
Benjamin Halladay
15 Mar 24
4
Sheldon L. Koenig
15 Mar 24
SC 13G/A
CVI Investments, Inc.
14 Feb 24
SC 13G/A
Two Seas Capital LP
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 114.83 mm | 114.83 mm | 114.83 mm | 114.83 mm | 114.83 mm | 114.83 mm |
Cash burn (monthly) | 7.88 mm | 7.88 mm | 9.18 mm | 12.98 mm | 6.44 mm | 11.74 mm |
Cash used (since last report) | 52.65 mm | 52.66 mm | 61.33 mm | 86.71 mm | 43.04 mm | 78.46 mm |
Cash remaining | 62.18 mm | 62.17 mm | 53.51 mm | 28.13 mm | 71.79 mm | 36.37 mm |
Runway (months of cash) | 7.9 | 7.9 | 5.8 | 2.2 | 11.1 | 3.1 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
14 Mar 24 | Sheldon L. Koenig | Common Stock | Grant | Acquire A | No | No | 0 | 454,000 | 0.00 | 766,816 |
14 Mar 24 | Sheldon L. Koenig | Stock Option Common Stock | Grant | Acquire A | No | No | 2.05 | 642,000 | 1.32 mm | 642,000 |
14 Mar 24 | Eric Warren | Common Stock | Grant | Acquire A | No | No | 0 | 100,000 | 0.00 | 168,318 |
14 Mar 24 | Eric Warren | Stock Option Common Stock | Grant | Acquire A | No | No | 2.05 | 150,000 | 307.50 k | 150,000 |
14 Mar 24 | Joanne M. Foody | Common Stock | Grant | Acquire A | No | No | 0 | 150,000 | 0.00 | 277,064 |
14 Mar 24 | Joanne M. Foody | Stock Option Common Stock | Grant | Acquire A | No | No | 2.05 | 200,000 | 410.00 k | 200,000 |
14 Mar 24 | Benjamin Looker | Common Stock | Grant | Acquire A | No | No | 0 | 100,000 | 0.00 | 183,663 |
14 Mar 24 | Benjamin Looker | Stock Option Common Stock | Grant | Acquire A | No | No | 2.05 | 150,000 | 307.50 k | 150,000 |
14 Mar 24 | Benjamin Halladay | Common Stock | Grant | Acquire A | No | No | 0 | 170,000 | 0.00 | 243,936 |
14 Mar 24 | Benjamin Halladay | Stock Option Common Stock | Grant | Acquire A | No | No | 2.05 | 200,000 | 410.00 k | 200,000 |
News
Applied Digital Reports Downbeat Results, Joins Nurix Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
12 Apr 24
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
11 Apr 24
Needham Reiterates Buy on Esperion Therapeutics, Maintains $8 Price Target
10 Apr 24
Why Esperion Therapeutics Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
8 Apr 24
Reported Sunday, Esperion Presents New Data From CLEAR Outcomes At ACC.24 Highlighting Value Of NEXLETOL® Tablets In Diverse Populations
8 Apr 24
Press releases
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
7 Apr 24
Actinium Pharmaceuticals (ATNM) Spearheading the Future of Oncology with Iomab-ACT's Innovative Clinical Trial
27 Mar 24
U.S. FDA Approves Broad New Labels for Esperion's NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
22 Mar 24
U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
22 Mar 24
CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events
22 Mar 24